vTv Therapeutics
Update in progressVTVT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
vTv Therapeutics Inc. is a late‑stage biopharmaceutical company focused on oral small‑molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin (TTP399), is an orally administered, liver‑selective glucokinase activator in Phase III trials for type 1 diabetes. The company is pursuing additional molecules across chronic‑disease indications. It has a license with Newsoara Biopharma for a phosphodiesterase‑4 inhibitors program. Founded 2015, HQ in High Point, NC.
Company score
- Sentiment
- -0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Paul J. Sekhri
- Founded2015
- Employees26
- Websitevtvtherapeutics.com
Identifiers
- ISINUS9183852048
- FIGIBBG009DT9XJ0
- CUSIP918385105
- CIK0001641489